14:14 , Mar 25, 2019 |  BioCentury  |  Emerging Company Profile

China Oncology Focus: funding combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
07:00 , Oct 13, 2011 |  BC Innovations  |  Cover Story

Going antiviral in brain cancer

A Karolinska Institute -led team has shown that targeting cytomegalovirus and/or inhibiting COX-2 could help treat medulloblastoma, the most common type of pediatric brain tumor. 1 The research presents a repurposing opportunity for companies with...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Clinical News

Capoxigem apricoxib: Phase II data

The double-blind, U.S. Phase II APRiCOT-L trial in 114 evaluable patients who previously failed a platinum-based chemotherapy regimen showed that once-daily 400 mg oral Capoxigem plus erlotinib missed the primary endpoint of significantly improving time...
00:20 , Jun 7, 2011 |  BC Extra  |  Clinical News

Tragara reports Capoxigem data

Tragara Pharmaceuticals Inc. (San Diego, Calif.) said Capoxigem apricoxib plus erlotinib missed the primary endpoint of significantly improving time to disease progression vs. placebo plus erlotinib in the Phase II APRiCOT-L trial to treat non-small...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Clinical News

SB1317: Phase I started

Tragara began an open-label, dose-ranging, U.S. Phase I trial to evaluate oral TG02. Tragara has exclusive, worldwide rights from S*BIO to develop and commercialize TG02 (see BioCentury, Jan. 26, 2009). S*BIO Pte. Ltd. , Singapore...
07:00 , Apr 12, 2010 |  BC Week In Review  |  Clinical News

Capoxigem apricoxib: Completed Phase II enrollment

Tragara completed enrollment of 128 patients in the double-blind, placebo-controlled Phase II APRiCOT-L trial evaluating 400 mg/day oral Capoigem apricoxib plus Tarceva erlotinib. Tarceva is marketed in the U.S. by OSI Pharmaceuticals Inc. (NASDAQ:OSIP, Melville,...
07:00 , Apr 27, 2009 |  BC Week In Review  |  Clinical News

Capoxigem apricoxib: Phase I data

Data from a Phase I trial in 20 patients with recurrent or metastatic NSCLC showed that 150 mg/day oral Tarceva erlotinib in combination with 100, 200 or 400 mg of oral Capoxigem produced 1 partial...
08:00 , Jan 26, 2009 |  BC Week In Review  |  Company News

S*BIO, Tragara deal

S*BIO granted Tragara an exclusive, worldwide license to develop and commercialize SB1317 . The oral inhibitor of FMS-like tyrosine kinase 3 ( FLT3 ) and cyclin dependent kinases (CDKs) is in preclinical development to treat...
00:31 , Jan 21, 2009 |  BC Extra  |  Company News

Tragara in-licenses S*BIO's SB1317

S*BIO (Singapore) granted Tragara (San Diego, Calif.) an exclusive, worldwide license to develop and commercialize SB1317 . The orally available inhibitor of FMS-like tyrosine kinase 3 ( FLT3 ) and cyclin dependent kinase ( CDK...